Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.
2.

Phytochemicals in hepatocellular cancer prevention.

Nishino H.

Nutr Cancer. 2009;61(6):789-91. doi: 10.1080/01635580903285031.

PMID:
20155617
3.

Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, Novelli V, Cipolla A, Fabbri C, Pezzoli A, Roda E.

J Hepatol. 1996 Feb;24(2):141-7.

PMID:
8907566
4.

Pilot clinical trial of the use of alpha-tocopherol for the prevention of hepatocellular carcinoma in patients with liver cirrhosis.

Takagi H, Kakizaki S, Sohara N, Sato K, Tsukioka G, Tago Y, Konaka K, Kabeya K, Kaneko M, Takayama H, Hashimoto Y, Yamada T, Takahashi H, Shimojo H, Nagamine T, Mori M.

Int J Vitam Nutr Res. 2003 Nov;73(6):411-5.

PMID:
14743544
5.

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S.

Lancet. 1995 Oct 21;346(8982):1051-5.

PMID:
7564784
6.

Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver.

Habu D, Shiomi S, Tamori A, Takeda T, Tanaka T, Kubo S, Nishiguchi S.

JAMA. 2004 Jul 21;292(3):358-61.

PMID:
15265851
7.

Viral hepatitis and hepatocellular carcinoma.

Sallie R, Di Bisceglie AM.

Gastroenterol Clin North Am. 1994 Sep;23(3):567-79. Review.

PMID:
7989095
8.

Potential role of lycopene in the treatment of hepatitis C and prevention of hepatocellular carcinoma.

Seren S, Mutchnick M, Hutchinson D, Harmanci O, Bayraktar Y, Mutchnick S, Sahin K, Kucuk O.

Nutr Cancer. 2008;60(6):729-35. doi: 10.1080/01635580802419772. Review.

PMID:
19005972
9.

Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study.

Ikeda K, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Arase Y, Murashima N, Chayama K, Kumada H.

J Gastroenterol Hepatol. 2001 Apr;16(4):406-15.

PMID:
11354279
10.

Colchicine delays the development of hepatocellular carcinoma in patients with hepatitis virus-related liver cirrhosis.

Arrieta O, Rodriguez-Diaz JL, Rosas-Camargo V, Morales-Espinosa D, Ponce de Leon S, Kershenobich D, Leon-Rodriguez E.

Cancer. 2006 Oct 15;107(8):1852-8.

11.

Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.

Tarao K, Fujiyama S, Ohkawa S, Miyakawa K, Tamai S, Hirokawa S, Masaki T, Tanaka K.

Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):164-9.

12.

Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan.

Chiang CJ, Yang YW, Chen JD, You SL, Yang HI, Lee MH, Lai MS, Chen CJ.

Hepatology. 2015 Apr;61(4):1154-62. doi: 10.1002/hep.27630. Epub 2015 Feb 10.

PMID:
25476749
13.

The prevention of cirrhosis and hepatocellular carcinoma.

Da Villa G.

Res Virol. 1997 Mar-Apr;148(2):89. No abstract available.

PMID:
9108605
14.

Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP).

Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, Almasio P, Solinas A, Brouwer JT, Thomas H, Realdi G, Corrocher R, Schalm SW.

J Hepatol. 1997 Jul;27(1):201-5.

PMID:
9252096
15.

Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis.

Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez-Tapias JM, Ventura M, Vall M, Bruguera M, Bru C, et al.

Lancet. 1989 Oct 28;2(8670):1004-6.

PMID:
2572739
16.

Serum antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma.

Sbolli G, Zanetti AR, Tanzi E, Cavanna L, Civardi G, Fornari F, Di Stasi M, Buscarini L.

J Med Virol. 1990 Mar;30(3):230-2.

PMID:
2160517
17.

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M.

Ann Intern Med. 1999 Aug 3;131(3):174-81.

PMID:
10428733
18.

Chronic liver disease in Peru: role of viral hepatitis.

Barham WB, Figueroa R, Phillips IA, Hyams KC.

J Med Virol. 1994 Feb;42(2):129-32.

PMID:
8158107
19.
20.

Alpha-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C.

Raedle J, Roth WK, Oremek G, Caspary WF, Zeuzem S.

Dig Dis Sci. 1995 Dec;40(12):2587-94.

PMID:
8536517

Supplemental Content

Support Center